Sunday, December 22, 2024

  • Twitter

September 2, 2024 5:17 PM

Sanofi’s mixed fortunes in MS drug trials has market focus on win

Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a study on a less common form of progressive MS. Investors fo...

Visitors: 3166129

Last updated on: 22nd December 2024